---
pmid: '27357661'
title: Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact
  architecture involving distant interdomain contacts.
authors:
- Guaitoli G
- Raimondi F
- Gilsbach BK
- Gómez-Llorente Y
- Deyaert E
- Renzi F
- Li X
- Schaffner A
- Jagtap PK
- Boldt K
- von Zweydorf F
- Gotthardt K
- Lorimer DD
- Yue Z
- Burgin A
- Janjic N
- Sattler M
- Versées W
- Ueffing M
- Ubarretxena-Belandia I
- Kortholt A
- Gloeckner CJ
journal: Proc Natl Acad Sci U S A
year: '2016'
full_text_available: false
pmcid: PMC4968714
doi: 10.1073/pnas.1523708113
---

# Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.
**Authors:** Guaitoli G, Raimondi F, Gilsbach BK, Gómez-Llorente Y, Deyaert E, Renzi F, Li X, Schaffner A, Jagtap PK, Boldt K, von Zweydorf F, Gotthardt K, Lorimer DD, Yue Z, Burgin A, Janjic N, Sattler M, Versées W, Ueffing M, Ubarretxena-Belandia I, Kortholt A, Gloeckner CJ
**Journal:** Proc Natl Acad Sci U S A (2016)
**DOI:** [10.1073/pnas.1523708113](https://doi.org/10.1073/pnas.1523708113)
**PMC:** [PMC4968714](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968714/)

## Abstract

1. Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4357-66. doi: 
10.1073/pnas.1523708113. Epub 2016 Jun 29.

Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact 
architecture involving distant interdomain contacts.

Guaitoli G(1), Raimondi F(2), Gilsbach BK(3), Gómez-Llorente Y(4), Deyaert E(5), 
Renzi F(4), Li X(6), Schaffner A(7), Jagtap PK(8), Boldt K(9), von Zweydorf 
F(1), Gotthardt K(10), Lorimer DD(11), Yue Z(6), Burgin A(12), Janjic N(13), 
Sattler M(8), Versées W(5), Ueffing M(9), Ubarretxena-Belandia I(14), Kortholt 
A(15), Gloeckner CJ(16).

Author information:
(1)German Center for Neurodegenerative Diseases, 72076 Tübingen, Germany; Center 
for Ophthalmology, Institute for Ophthalmic Research, Eberhard Karls University, 
72076 Tübingen, Germany;
(2)Department of Life Sciences, University of Modena and Reggio Emilia, 41125 
Modena, Italy; Cell Networks, University of Heidelberg, 69120 Heidelberg, 
Germany;
(3)German Center for Neurodegenerative Diseases, 72076 Tübingen, Germany; 
Department of Cell Biochemistry, University of Groningen, Groningen 9747 AG, The 
Netherlands; Structural Biology Group, Max Planck Institute for Molecular 
Physiology, 44227 Dortmund, Germany;
(4)Department of Structural and Chemical Biology, Icahn School of Medicine at 
Mount Sinai, New York, NY 10029;
(5)Structural Biology Brussels, Vrije Universiteit Brussel, 1050 Brussels, 
Belgium; Vlaams Instituut voor Biotechnologie, Structural Biology Research 
Center, Vrije Universiteit Brussel, 1050 Brussels, Belgium;
(6)Departments of Neurology and Neuroscience, Friedman Brain Institute, Icahn 
School of Medicine at Mount Sinai, New York, NY 10029;
(7)Department of Structural and Chemical Biology, Icahn School of Medicine at 
Mount Sinai, New York, NY 10029; Departments of Neurology and Neuroscience, 
Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 
10029;
(8)Center for Integrated Protein Science Munich at Department of Chemistry, 
Technische Universität München, 85747 Garching, Germany; Institute of Structural 
Biology, Helmholtz Zentrum München, 85764 Munich, Germany;
(9)Center for Ophthalmology, Institute for Ophthalmic Research, Eberhard Karls 
University, 72076 Tübingen, Germany;
(10)Structural Biology Group, Max Planck Institute for Molecular Physiology, 
44227 Dortmund, Germany;
(11)Beryllium Discovery Corporation, Bainbridge Island, WA 98110;
(12)Broad Institute, Cambridge, MA 02142;
(13)SomaLogic, Boulder, CO 80301.
(14)Department of Structural and Chemical Biology, Icahn School of Medicine at 
Mount Sinai, New York, NY 10029; iban.ubarretxena@mssm.edu a.kortholt@rug.nl 
johannes.gloeckner@dzne.de.
(15)Department of Cell Biochemistry, University of Groningen, Groningen 9747 AG, 
The Netherlands; iban.ubarretxena@mssm.edu a.kortholt@rug.nl 
johannes.gloeckner@dzne.de.
(16)German Center for Neurodegenerative Diseases, 72076 Tübingen, Germany; 
Center for Ophthalmology, Institute for Ophthalmic Research, Eberhard Karls 
University, 72076 Tübingen, Germany; iban.ubarretxena@mssm.edu a.kortholt@rug.nl 
johannes.gloeckner@dzne.de.

Comment in
    Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):8346-8. doi: 
10.1073/pnas.1609311113.

Leucine-rich repeat kinase 2 (LRRK2) is a large, multidomain protein containing 
two catalytic domains: a Ras of complex proteins (Roc) G-domain and a kinase 
domain. Mutations associated with familial and sporadic Parkinson's disease (PD) 
have been identified in both catalytic domains, as well as in several of its 
multiple putative regulatory domains. Several of these mutations have been 
linked to increased kinase activity. Despite the role of LRRK2 in the 
pathogenesis of PD, little is known about its overall architecture and how 
PD-linked mutations alter its function and enzymatic activities. Here, we have 
modeled the 3D structure of dimeric, full-length LRRK2 by combining domain-based 
homology models with multiple experimental constraints provided by chemical 
cross-linking combined with mass spectrometry, negative-stain EM, and 
small-angle X-ray scattering. Our model reveals dimeric LRRK2 has a compact 
overall architecture with a tight, multidomain organization. Close contacts 
between the N-terminal ankyrin and C-terminal WD40 domains, and their 
proximity-together with the LRR domain-to the kinase domain suggest an 
intramolecular mechanism for LRRK2 kinase activity regulation. Overall, our 
studies provide, to our knowledge, the first structural framework for 
understanding the role of the different domains of full-length LRRK2 in the 
pathogenesis of PD.

DOI: 10.1073/pnas.1523708113
PMCID: PMC4968714
PMID: 27357661 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no conflict of interest.
